id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-1326-2177,FDA,FDA-2021-N-1326,MEMORANDUM FOR THE RECORD,Other,Memorandum,2022-04-28T04:00:00Z,2022,4,2022-04-28T04:00:00Z,,2022-04-28T20:49:58Z,,0,0,090000648503fe6b
FDA-2021-N-1326-1568,FDA,FDA-2021-N-1326,Part 15 Hearing Presentations,Other,Additional Information,2022-04-11T04:00:00Z,2022,4,2022-04-11T04:00:00Z,,2022-04-11T19:41:05Z,,0,0,090000648500ca54
FDA-2021-N-1326-1567,FDA,FDA-2021-N-1326,Part 15 Hearing - transcript,Other,Transcript(s),2022-04-11T04:00:00Z,2022,4,2022-04-11T04:00:00Z,,2022-04-11T19:40:29Z,,0,0,090000648500ca52
FDA-2021-N-1326-1566,FDA,FDA-2021-N-1326,Part 15 Hearing - video,Other,Additional Information,2022-04-11T04:00:00Z,2022,4,2022-04-11T04:00:00Z,,2022-04-11T18:34:08Z,,0,0,090000648500bb39
FDA-2021-N-1326-1539,FDA,FDA-2021-N-1326,Scientific Data and Information Related to the Residue of Carcinogenic Concern for the New Animal Drug Carbadox; Public Hearing; Request for Comments; Extension of Comment Period,Proposed Rule,Extension of Comment Period,2022-03-31T04:00:00Z,2022,3,2022-03-31T04:00:00Z,,2022-03-31T12:50:05Z,2022-06762,0,0,0900006484fefb12
FDA-2021-N-1326-0381,FDA,FDA-2021-N-1326,Request for Extension from Covington & Burling LLP,Other,Request for Extension,2022-03-18T04:00:00Z,2022,3,2022-06-15T04:00:00Z,,2022-06-15T15:35:55Z,,0,0,0900006484fce0c2
FDA-2021-N-1326-0014,FDA,FDA-2021-N-1326,Part 15 Public Hearing Agenda - Final,Other,Agenda,2022-03-11T05:00:00Z,2022,3,2022-03-11T05:00:00Z,,2022-03-11T18:33:35Z,,0,0,0900006484fc4095
FDA-2021-N-1326-0012,FDA,FDA-2021-N-1326,Part 15 Public Hearing: Scientific Data and Information Related to the Residue of Carcinogenic Concern for the New Animal Drug Carbadox,Other,Agenda,2022-03-10T05:00:00Z,2022,3,2022-03-10T05:00:00Z,,2022-03-10T12:19:51Z,,0,0,0900006484fc1ef7
FDA-2021-N-1326-0009,FDA,FDA-2021-N-1326,"Part 15 Public Hearing: Scientific Data and Information Related to the Residue of
Carcinogenic Concern for the New Animal Drug Carbadox",Other,Agenda,2022-03-04T05:00:00Z,2022,3,2022-03-04T05:00:00Z,,2022-03-04T19:05:43Z,,0,0,0900006484fba380
FDA-2021-N-1326-0003,FDA,FDA-2021-N-1326,Determination of Carbadox (As Quinoxaline-2-Carboxylic (QCA) Residues in Swine Liver and Muscle Tissues after Drug Withdrawal,Other,Additional Information,2022-02-18T05:00:00Z,2022,2,2022-02-18T05:00:00Z,,2022-02-18T13:07:07Z,,0,0,0900006484f82f68
FDA-2021-N-1326-0004,FDA,FDA-2021-N-1326,"CVM Response to Phibro Animal Health Corporation’s September 18, 2020 Comments on CVM’s July 20, 2020 Proposed Order to Revoke the Regulatory Method for Carbadox",Other,Additional Information,2022-02-18T05:00:00Z,2022,2,2022-02-18T05:00:00Z,,2022-06-19T01:51:03Z,,0,0,0900006484f82f6a
FDA-2021-N-1326-0001,FDA,FDA-2021-N-1326,Scientific Data and Information Related to the Residue of Carcinogenic Concern for the New Animal Drug Carbadox; Public Hearing; Request for Comments,Proposed Rule,Public Hearing,2022-01-13T05:00:00Z,2022,1,2022-01-13T05:00:00Z,2022-06-11T03:59:59Z,2022-06-16T01:00:32Z,2022-00475,0,0,0900006484f1e918